IP Library › Granted Patent US 12,215,155
Granted Patent B2
US 12,215,155 · App. 18/446,032 · Granted Feb 4, 2025

Antibodies binding to CD3 and CD19

Inventors: Anne Freimoser-Grundschober (Schlieren, CH); Maria Valeria Gonzalez Nicolini (Schlieren, CH); Ralf Hosse (Schlieren, CH); Alexander Knaupp (Penzberg, DE); Ekkehard Moessner (Schlieren, CH); Wolfgang Richter (Basel, CH); Halina Trochanowska (Schlieren, CH); Pablo Umaña (Schlieren, CH); Christian Klein (Schlieren, CH); Inja Waldhauer (Schlieren, CH)
Assignee: Hoffmann-La Roche Inc.
C07K16/2809A61P35/00C07K16/30A61K2039/505C07K2317/52C07K2317/55C07K2317/565
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,215,155
App. No.
18/446,032
Granted
Feb 4, 2025
Kind
B2
Abstract

The present invention generally relates to antibodies that bind to CD3 and CD19, e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Claims (111)

1. A method of treating an autoimmune disease in an individual, comprising administering to said individual an effective amount of an antibody that binds to CD3 and CD19, wherein the antibody comprises:

(a) a first antigen binding domain that binds to CD3, wherein the first antigen binding domain is a Fab molecule wherein the variable domains VL and VH of the Fab light chain and the Fab heavy chain are replaced by each other, and wherein the first antigen binding domain comprises a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 2, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 3, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 5, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 8, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 9, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 10;

(b) a second antigen binding domain and a third antigen binding domain that bind to CD19, wherein the second antigen binding domain and the third antigen binding domain are each a conventional Fab molecule, and wherein each of the second antigen binding domain and the third antigen binding domain comprises a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 15, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 16, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 17, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 19, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 20, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 21; and

(c) an Fc domain composed of a first subunit and a second subunit;

wherein the second antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding domain, and the first antigen binding domain and the third antigen binding domain are each fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain.

2. The method of claim 1 , wherein:

(a) the first antigen binding domain comprises a VH comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 7 and a VL comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 11; and

(b) each of the second antigen binding domain and the third antigen binding domain comprises a VH comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 18 and a VL comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 22.

3. The method of claim 1 , wherein in the constant domain CL of each of the second antigen binding domain and the third antigen binding domain the amino acid at position 124 is substituted by lysine (K) (numbering according to Kabat) and the amino acid at position 123 is substituted by lysine (K) or arginine (R) (numbering according to Kabat), and wherein in the constant domain CH1 of each of the second antigen binding domain and the third antigen binding domain the amino acid at position 147 is substituted by glutamic acid (E) (numbering according to Kabat EU index) and the amino acid at position 213 is substituted by glutamic acid (E) (numbering according to Kabat EU index).

4. The method of claim 1 , wherein the Fc domain is an IgG Fc domain.

5. The method of claim 1 , wherein the Fc domain is a human IgG 1 Fc domain, and wherein in the first subunit of the Fc domain the threonine residue at position 366 is replaced with a tryptophan residue (T366W) and the serine residue at position 354 is replaced with a cysteine residue (S354C), and in the second subunit of the Fc domain the tyrosine residue at position 407 is replaced with a valine residue (Y407V), the threonine residue at position 366 is replaced with a serine residue (T366S), the leucine residue at position 368 is replaced with an alanine residue (L368A), and the tyrosine residue at position 349 is replaced with a cysteine residue (Y349C) (numbering according to Kabat EU index), and wherein further in each of the first subunit and the second subunit of the Fc domain the leucine residue at position 234 is replaced with an alanine residue (L234A), the leucine residue at position 235 is replaced with an alanine residue (L235A), and the proline residue at position 329 is replaced by a glycine residue (P329G) (numbering according to Kabat EU index).

6. The method of claim 1 , wherein the antibody comprises a polypeptide comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 39, a polypeptide comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 24, two polypeptides each comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 25, and a polypeptide comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 27.

7. The method of claim 1 , wherein the autoimmune disease is lupus.

8. The method of claim 7 , wherein the lupus is systemic lupus erythematosus (SLE) or lupus nephritis (LN).

9. A method of treating an autoimmune disease in an individual, comprising administering to said individual an effective amount of an antibody that binds to CD3 and CD19, wherein the antibody comprises:

(a) a first antigen binding domain that binds to CD3, wherein the first antigen binding domain is a Fab molecule wherein the variable domains VL and VH of the Fab light chain and the Fab heavy chain are replaced by each other, and wherein the VH comprises the amino acid sequence of SEQ ID NO: 7 and the VL comprises the amino acid sequence of SEQ ID NO: 11;

(b) a second antigen binding domain and a third antigen binding domain that bind to CD19, wherein the second antigen binding domain and the third antigen binding domain are each a conventional Fab molecule, and wherein each of the second antigen binding domain and the third antigen binding domain comprises a VH comprising the amino acid sequence of SEQ ID NO: 18 and a VL comprising the amino acid sequence of SEQ ID NO: 22; and

(c) an Fc domain composed of a first subunit and a second subunit;

wherein the second antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding domain, and the first antigen binding domain and the third antigen binding domain are each fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain.

10. The method of claim 9 , wherein

in the constant domain CL of each of the second antigen binding domain and the third antigen binding domain the amino acid at position 124 is substituted by lysine (K) (numbering according to Kabat) and the amino acid at position 123 is substituted by lysine (K) or arginine (R) (numbering according to Kabat), and wherein in the constant domain CH1 of each of the second antigen binding domain and the third antigen binding domain the amino acid at position 147 is substituted by glutamic acid (E) (numbering according to Kabat EU index) and the amino acid at position 213 is substituted by glutamic acid (E) (numbering according to Kabat EU index).

11. The method of claim 9 , wherein the Fc domain is an IgG Fc domain.

12. The method of claim 9 , wherein the Fc domain is a human IgG 1 Fc domain, and wherein in the first subunit of the Fc domain the threonine residue at position 366 is replaced with a tryptophan residue (T366W) and the serine residue at position 354 is replaced with a cysteine residue (S354C), and in the second subunit of the Fc domain the tyrosine residue at position 407 is replaced with a valine residue (Y407V), the threonine residue at position 366 is replaced with a serine residue (T366S), the leucine residue at position 368 is replaced with an alanine residue (L368A), and the tyrosine residue at position 349 is replaced with a cysteine residue (Y349C) (numbering according to Kabat EU index), and wherein further in each of the first subunit and the second subunit of the Fc domain the leucine residue at position 234 is replaced with an alanine residue (L234A), the leucine residue at position 235 is replaced with an alanine residue (L235A), and the proline residue at position 329 is replaced by a glycine residue (P329G) (numbering according to Kabat EU index).

13. The method of claim 9 , wherein the antibody comprises a polypeptide comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 39, a polypeptide comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 24, two polypeptides each comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 25, and a polypeptide comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 27.

14. The method of claim 9 , wherein the autoimmune disease is lupus.

15. The method of claim 14 , wherein the lupus is SLE or LN.

16. A method of treating an autoimmune disease in an individual, comprising administering to said individual an effective amount of an antibody that binds to CD3 and CD19, wherein the antibody comprises a polypeptide comprising the amino acid sequence of SEQ ID NO: 39, a polypeptide comprising the amino acid sequence of SEQ ID NO: 24, two polypeptides each comprising the amino acid sequence of SEQ ID NO: 25, and a polypeptide comprising the amino acid sequence of SEQ ID NO: 27.

17. The method of claim 16 , wherein the autoimmune disease is lupus.

18. The method of claim 17 , wherein the lupus is SLE or LN.

19. A method of treating an autoimmune disease in an individual, comprising administering to said individual an effective amount of an antibody that binds to CD3 and CD19, wherein the antibody comprises:

(a) a first antigen binding domain that binds to CD3, wherein the first antigen binding domain is a Fab molecule wherein the variable domains VL and VH of the Fab light chain and the Fab heavy chain are replaced by each other, and wherein the first antigen binding domain comprises a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 2, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 3, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 5, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 8, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 9, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 10;

(b) a second antigen binding domain and a third antigen binding domain that bind to CD19, wherein the second antigen binding domain and the third antigen binding domain are each a conventional Fab molecule, and wherein each of the second antigen binding domain and the third antigen binding domain comprises a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 15, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 16, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 17, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 19, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 20, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 21; and

(c) an Fc domain composed of a first subunit and a second subunit;

wherein in the constant domain CL of each of the second antigen binding domain and the third antigen binding domain the amino acid at position 124 is substituted by lysine (K) (numbering according to Kabat) and the amino acid at position 123 is substituted by arginine (R) (numbering according to Kabat), and wherein in the constant domain CH1 of each of the second antigen binding domain and the third antigen binding domain the amino acid at position 147 is substituted by glutamic acid (E) (numbering according to Kabat EU index) and the amino acid at position 213 is substituted by glutamic acid (E) (numbering according to Kabat EU index);

and wherein the second antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding domain, and the first antigen binding domain and the third antigen binding domain are each fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain.

20. The method of claim 19 , wherein the Fc domain is a human IgG 1 Fc domain, and wherein in the first subunit of the Fc domain the threonine residue at position 366 is replaced with a tryptophan residue (T366W) and the serine residue at position 354 is replaced with a cysteine residue (S354C), and in the second subunit of the Fc domain the tyrosine residue at position 407 is replaced with a valine residue (Y407V), the threonine residue at position 366 is replaced with a serine residue (T366S), the leucine residue at position 368 is replaced with an alanine residue (L368A), and the tyrosine residue at position 349 is replaced with a cysteine residue (Y349C) (numbering according to Kabat EU index), and wherein further in each of the first subunit and the second subunit of the Fc domain the leucine residue at position 234 is replaced with an alanine residue (L234A), the leucine residue at position 235 is replaced with an alanine residue (L235A), and the proline residue at position 329 is replaced by a glycine residue (P329G) (numbering according to Kabat EU index).

21. The method of claim 20 , wherein the antibody comprises a polypeptide comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 39, a polypeptide comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 24, two polypeptides each comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 25, and a polypeptide comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 27.

22. A method of treating lupus in an individual, comprising administering to said individual an effective amount of an antibody that binds to CD3 and CD19, wherein the antibody comprises:

(a) a first antigen binding domain that binds to CD3, wherein the first antigen binding domain is a Fab molecule wherein the variable domains VL and VH of the Fab light chain and the Fab heavy chain are replaced by each other, and wherein the first antigen binding domain comprises a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 2, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 3, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 5, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 8, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 9, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 10;

(b) a second antigen binding domain and a third antigen binding domain that bind to CD19, wherein the second antigen binding domain and the third antigen binding domain are each a conventional Fab molecule, and wherein each of the second antigen binding domain and the third antigen binding domain comprises a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 15, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 16, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 17, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 19, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 20, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 21; and

(c) an Fc domain composed of a first subunit and a second subunit;

wherein in the constant domain CL of each of the second antigen binding domain and the third antigen binding domain the amino acid at position 124 is substituted by lysine (K) (numbering according to Kabat) and the amino acid at position 123 is substituted by arginine (R) (numbering according to Kabat), and wherein in the constant domain CH1 of each of the second antigen binding domain and the third antigen binding domain the amino acid at position 147 is substituted by glutamic acid (E) (numbering according to Kabat EU index) and the amino acid at position 213 is substituted by glutamic acid (E) (numbering according to Kabat EU index);

and wherein the second antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding domain, and the first antigen binding domain and the third antigen binding domain are each fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain.

23. The method of claim 22 , wherein the Fc domain is a human IgG 1 Fc domain, and wherein in the first subunit of the Fc domain the threonine residue at position 366 is replaced with a tryptophan residue (T366W) and the serine residue at position 354 is replaced with a cysteine residue (S354C), and in the second subunit of the Fc domain the tyrosine residue at position 407 is replaced with a valine residue (Y407V), the threonine residue at position 366 is replaced with a serine residue (T366S), the leucine residue at position 368 is replaced with an alanine residue (L368A), and the tyrosine residue at position 349 is replaced with a cysteine residue (Y349C) (numbering according to Kabat EU index), and wherein further in each of the first subunit and the second subunit of the Fc domain the leucine residue at position 234 is replaced with an alanine residue (L234A), the leucine residue at position 235 is replaced with an alanine residue (L235A), and the proline residue at position 329 is replaced by a glycine residue (P329G) (numbering according to Kabat EU index).

24. The method of claim 22 , wherein the antibody comprises a polypeptide comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 39, a polypeptide comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 24, two polypeptides each comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 25, and a polypeptide comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 27.

25. A method of treating SLE in an individual, comprising administering to said individual an effective amount of an antibody that binds to CD3 and CD19, wherein the antibody comprises:

(a) a first antigen binding domain that binds to CD3, wherein the first antigen binding domain is a Fab molecule wherein the variable domains VL and VH of the Fab light chain and the Fab heavy chain are replaced by each other, and wherein the first antigen binding domain comprises a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 2, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 3, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 5, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 8, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 9, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 10;

(b) a second antigen binding domain and a third antigen binding domain that bind to CD19, wherein the second antigen binding domain and the third antigen binding domain are each a conventional Fab molecule, and wherein each of the second antigen binding domain and the third antigen binding domain comprises a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 15, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 16, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 17, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 19, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 20, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 21; and

(c) an Fc domain composed of a first subunit and a second subunit;

wherein in the constant domain CL of each of the second antigen binding domain and the third antigen binding domain the amino acid at position 124 is substituted by lysine (K) (numbering according to Kabat) and the amino acid at position 123 is substituted by arginine (R) (numbering according to Kabat), and wherein in the constant domain CH1 of each of the second antigen binding domain and the third antigen binding domain the amino acid at position 147 is substituted by glutamic acid (E) (numbering according to Kabat EU index) and the amino acid at position 213 is substituted by glutamic acid (E) (numbering according to Kabat EU index);

and wherein the second antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding domain, and the first antigen binding domain and the third antigen binding domain are each fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain.

26. The method of claim 25 , wherein the Fc domain is a human IgG 1 Fc domain, and wherein in the first subunit of the Fc domain the threonine residue at position 366 is replaced with a tryptophan residue (T366W) and the serine residue at position 354 is replaced with a cysteine residue (S354C), and in the second subunit of the Fc domain the tyrosine residue at position 407 is replaced with a valine residue (Y407V), the threonine residue at position 366 is replaced with a serine residue (T366S), the leucine residue at position 368 is replaced with an alanine residue (L368A), and the tyrosine residue at position 349 is replaced with a cysteine residue (Y349C) (numbering according to Kabat EU index), and wherein further in each of the first subunit and the second subunit of the Fc domain the leucine residue at position 234 is replaced with an alanine residue (L234A), the leucine residue at position 235 is replaced with an alanine residue (L235A), and the proline residue at position 329 is replaced by a glycine residue (P329G) (numbering according to Kabat EU index).

27. The method of claim 25 , wherein the antibody comprises a polypeptide comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 39, a polypeptide comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 24, two polypeptides each comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 25, and a polypeptide comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 27.

28. A method of treating LN in an individual, comprising administering to said individual an effective amount of an antibody that binds to CD3 and CD19, wherein the antibody comprises:

(a) a first antigen binding domain that binds to CD3, wherein the first antigen binding domain is a Fab molecule wherein the variable domains VL and VH of the Fab light chain and the Fab heavy chain are replaced by each other, and wherein the first antigen binding domain comprises a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 2, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 3, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 5, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 8, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 9, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 10;

(b) a second antigen binding domain and a third antigen binding domain that bind to CD19, wherein the second antigen binding domain and the third antigen binding domain are each a conventional Fab molecule, and wherein each of the second antigen binding domain and the third antigen binding domain comprises a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 15, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 16, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 17, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 19, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 20, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 21; and

(c) an Fc domain composed of a first subunit and a second subunit;

wherein in the constant domain CL of each of the second antigen binding domain and the third antigen binding domain the amino acid at position 124 is substituted by lysine (K) (numbering according to Kabat) and the amino acid at position 123 is substituted by arginine (R) (numbering according to Kabat), and wherein in the constant domain CH1 of each of the second antigen binding domain and the third antigen binding domain the amino acid at position 147 is substituted by glutamic acid (E) (numbering according to Kabat EU index) and the amino acid at position 213 is substituted by glutamic acid (E) (numbering according to Kabat EU index);

and wherein the second antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding domain, and the first antigen binding domain and the third antigen binding domain are each fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain.

29. The method of claim 28 , wherein the Fc domain is a human IgG 1 Fc domain, and wherein in the first subunit of the Fc domain the threonine residue at position 366 is replaced with a tryptophan residue (T366W) and the serine residue at position 354 is replaced with a cysteine residue (S354C), and in the second subunit of the Fc domain the tyrosine residue at position 407 is replaced with a valine residue (Y407V), the threonine residue at position 366 is replaced with a serine residue (T366S), the leucine residue at position 368 is replaced with an alanine residue (L368A), and the tyrosine residue at position 349 is replaced with a cysteine residue (Y349C) (numbering according to Kabat EU index), and wherein further in each of the first subunit and the second subunit of the Fc domain the leucine residue at position 234 is replaced with an alanine residue (L234A), the leucine residue at position 235 is replaced with an alanine residue (L235A), and the proline residue at position 329 is replaced by a glycine residue (P329G) (numbering according to Kabat EU index).

30. The method of claim 28 , wherein the antibody comprises a polypeptide comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 39, a polypeptide comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 24, two polypeptides each comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 25, and a polypeptide comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 27.

31. A method of treating an autoimmune disease in an individual, comprising administering to said individual an effective amount of an antibody that binds to CD3 and CD19, wherein the antibody comprises:

(a) a first antigen binding domain that binds to CD3, wherein the first antigen binding domain is a Fab molecule wherein the variable domains VL and VH of the Fab light chain and the Fab heavy chain are replaced by each other, and wherein the first antigen binding domain (i) comprises a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 2, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 3, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 5, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 8, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 9, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 10, and/or (ii) comprises a VH comprising the amino acid sequence of SEQ ID NO: 7 and a VL comprising the amino acid sequence of SEQ ID NO: 11;

(b) a second antigen binding domain and a third antigen binding domain that bind to CD19, wherein the second antigen binding domain and the third antigen binding domain are each a conventional Fab molecule, and wherein each of the second antigen binding domain and the third antigen binding domain (i) comprises a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 15, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 16, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 17, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 19, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 20, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 21, and/or (ii) comprises a VH comprising the amino acid sequence of SEQ ID NO: 18 and a VL comprising the amino acid sequence of SEQ ID NO: 22; and

(c) an Fc domain composed of a first subunit and a second subunit, wherein the Fc domain is an IgG Fc domain;

wherein the second antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding domain, and the first antigen binding domain and the third antigen binding domain are each fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain.

32. The method of claim 31 , wherein the Fc domain is a human IgG 1 Fc domain, and wherein in the first subunit of the Fc domain the threonine residue at position 366 is replaced with a tryptophan residue (T366W) and the serine residue at position 354 is replaced with a cysteine residue (S354C), and in the second subunit of the Fc domain the tyrosine residue at position 407 is replaced with a valine residue (Y407V), the threonine residue at position 366 is replaced with a serine residue (T366S), the leucine residue at position 368 is replaced with an alanine residue (L368A), and the tyrosine residue at position 349 is replaced with a cysteine residue (Y349C) (numbering according to Kabat EU index), and wherein further in each of the first subunit and the second subunit of the Fc domain the leucine residue at position 234 is replaced with an alanine residue (L234A), the leucine residue at position 235 is replaced with an alanine residue (L235A), and the proline residue at position 329 is replaced by a glycine residue (P329G) (numbering according to Kabat EU index).

33. The method of claim 31 , wherein the antibody comprises a polypeptide comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 39, a polypeptide comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 24, two polypeptides each comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 25, and a polypeptide comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 27.

34. A method of treating lupus in an individual, comprising administering to said individual an effective amount of an antibody that binds to CD3 and CD19, wherein the antibody comprises:

(a) a first antigen binding domain that binds to CD3, wherein the first antigen binding domain is a Fab molecule wherein the variable domains VL and VH of the Fab light chain and the Fab heavy chain are replaced by each other, and wherein the first antigen binding domain (i) comprises a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 2, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 3, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 5, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 8, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 9, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 10, and/or (ii) comprises a VH comprising the amino acid sequence of SEQ ID NO: 7 and a VL comprising the amino acid sequence of SEQ ID NO: 11;

(b) a second antigen binding domain and a third antigen binding domain that bind to CD19, wherein the second antigen binding domain and the third antigen binding domain are each a conventional Fab molecule, and wherein each of the second antigen binding domain and the third antigen binding domain (i) comprises a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 15, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 16, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 17, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 19, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 20, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 21, and/or (ii) comprises a VH comprising the amino acid sequence of SEQ ID NO: 18 and a VL comprising the amino acid sequence of SEQ ID NO: 22; and

(c) an Fc domain composed of a first subunit and a second subunit, wherein the Fc domain is an IgG Fc domain;

wherein the second antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding domain, and the first antigen binding domain and the third antigen binding domain are each fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain.

35. The method of claim 34 , wherein the Fc domain is a human IgG 1 Fc domain, and wherein in the first subunit of the Fc domain the threonine residue at position 366 is replaced with a tryptophan residue (T366W) and the serine residue at position 354 is replaced with a cysteine residue (S354C), and in the second subunit of the Fc domain the tyrosine residue at position 407 is replaced with a valine residue (Y407V), the threonine residue at position 366 is replaced with a serine residue (T366S), the leucine residue at position 368 is replaced with an alanine residue (L368A), and the tyrosine residue at position 349 is replaced with a cysteine residue (Y349C) (numbering according to Kabat EU index), and wherein further in each of the first subunit and the second subunit of the Fc domain the leucine residue at position 234 is replaced with an alanine residue (L234A), the leucine residue at position 235 is replaced with an alanine residue (L235A), and the proline residue at position 329 is replaced by a glycine residue (P329G) (numbering according to Kabat EU index).

36. The method of claim 34 , wherein the antibody comprises a polypeptide comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 39, a polypeptide comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 24, two polypeptides each comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 25, and a polypeptide comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 27.

37. A method of treating SLE in an individual, comprising administering to said individual an effective amount of an antibody that binds to CD3 and CD19, wherein the antibody comprises:

(a) a first antigen binding domain that binds to CD3, wherein the first antigen binding domain is a Fab molecule wherein the variable domains VL and VH of the Fab light chain and the Fab heavy chain are replaced by each other, and wherein the first antigen binding domain (i) comprises a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 2, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 3, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 5, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 8, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 9, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 10, and/or (ii) comprises a VH comprising the amino acid sequence of SEQ ID NO: 7 and a VL comprising the amino acid sequence of SEQ ID NO: 11;

(b) a second antigen binding domain and a third antigen binding domain that bind to CD19, wherein the second antigen binding domain and the third antigen binding domain are each a conventional Fab molecule, and wherein each of the second antigen binding domain and the third antigen binding domain (i) comprises a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 15, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 16, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 17, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 19, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 20, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 21, and/or (ii) comprises a VH comprising the amino acid sequence of SEQ ID NO: 18 and a VL comprising the amino acid sequence of SEQ ID NO: 22; and

(c) an Fc domain composed of a first subunit and a second subunit, wherein the Fc domain is an IgG Fc domain;

wherein the second antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding domain, and the first antigen binding domain and the third antigen binding domain are each fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain.

38. The method of claim 37 , wherein the Fc domain is a human IgG 1 Fc domain, and wherein in the first subunit of the Fc domain the threonine residue at position 366 is replaced with a tryptophan residue (T366W) and the serine residue at position 354 is replaced with a cysteine residue (S354C), and in the second subunit of the Fc domain the tyrosine residue at position 407 is replaced with a valine residue (Y407V), the threonine residue at position 366 is replaced with a serine residue (T366S), the leucine residue at position 368 is replaced with an alanine residue (L368A), and the tyrosine residue at position 349 is replaced with a cysteine residue (Y349C) (numbering according to Kabat EU index), and wherein further in each of the first subunit and the second subunit of the Fc domain the leucine residue at position 234 is replaced with an alanine residue (L234A), the leucine residue at position 235 is replaced with an alanine residue (L235A), and the proline residue at position 329 is replaced by a glycine residue (P329G) (numbering according to Kabat EU index).

39. The method of claim 37 , wherein the antibody comprises a polypeptide comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 39, a polypeptide comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 24, two polypeptides each comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 25, and a polypeptide comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 27.

40. A method of treating LN in an individual, comprising administering to said individual an effective amount of an antibody that binds to CD3 and CD19, wherein the antibody comprises:

(a) a first antigen binding domain that binds to CD3, wherein the first antigen binding domain is a Fab molecule wherein the variable domains VL and VH of the Fab light chain and the Fab heavy chain are replaced by each other, and wherein the first antigen binding domain (i) comprises a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 2, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 3, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 5, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 8, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 9, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 10, and/or (ii) comprises a VH comprising the amino acid sequence of SEQ ID NO: 7 and a VL comprising the amino acid sequence of SEQ ID NO: 11;

(b) a second antigen binding domain and a third antigen binding domain that bind to CD19, wherein the second antigen binding domain and the third antigen binding domain are each a conventional Fab molecule, and wherein each of the second antigen binding domain and the third antigen binding domain (i) comprises a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 15, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 16, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 17, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 19, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 20, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 21, and/or (ii) comprises a VH comprising the amino acid sequence of SEQ ID NO: 18 and a VL comprising the amino acid sequence of SEQ ID NO: 22; and

(c) an Fc domain composed of a first subunit and a second subunit, wherein the Fc domain is an IgG Fc domain;

wherein the second antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding domain, and the first antigen binding domain and the third antigen binding domain are each fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain.

41. The method of claim 40 , wherein the Fc domain is a human IgG 1 Fc domain, and wherein in the first subunit of the Fc domain the threonine residue at position 366 is replaced with a tryptophan residue (T366W) and the serine residue at position 354 is replaced with a cysteine residue (S354C), and in the second subunit of the Fc domain the tyrosine residue at position 407 is replaced with a valine residue (Y407V), the threonine residue at position 366 is replaced with a serine residue (T366S), the leucine residue at position 368 is replaced with an alanine residue (L368A), and the tyrosine residue at position 349 is replaced with a cysteine residue (Y349C) (numbering according to Kabat EU index), and wherein further in each of the first subunit and the second subunit of the Fc domain the leucine residue at position 234 is replaced with an alanine residue (L234A), the leucine residue at position 235 is replaced with an alanine residue (L235A), and the proline residue at position 329 is replaced by a glycine residue (P329G) (numbering according to Kabat EU index).

42. The method of claim 40 , wherein the antibody comprises a polypeptide comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 39, a polypeptide comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 24, two polypeptides each comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 25, and a polypeptide comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 27.

43. The method of claim 1 , wherein the second antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding domain via a peptide linker.

44. The method of claim 43 , wherein the peptide linker comprises the amino acid sequence GGGGSGGGGS (SEQ ID NO: 48).

45. The method of claim 9 , wherein the second antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding domain via a peptide linker.

46. The method of claim 45 , wherein the peptide linker comprises the amino acid sequence GGGGSGGGGS (SEQ ID NO: 48).

47. The method of claim 16 , wherein the second antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding domain via a peptide linker.

48. The method of claim 47 , wherein the peptide linker comprises the amino acid sequence GGGGSGGGGS (SEQ ID NO: 48).

49. The method of claim 19 , wherein the second antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding domain via a peptide linker.

50. The method of claim 49 , wherein the peptide linker comprises the amino acid sequence GGGGSGGGGS (SEQ ID NO: 48).

51. The method of claim 22 , wherein the second antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding domain via a peptide linker.

52. The method of claim 51 , wherein the peptide linker comprises the amino acid sequence GGGGSGGGGS (SEQ ID NO: 48).

53. The method of claim 25 , wherein the second antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding domain via a peptide linker.

54. The method of claim 53 , wherein the peptide linker comprises the amino acid sequence GGGGSGGGGS (SEQ ID NO: 48).

55. The method of claim 28 , wherein the second antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding domain via a peptide linker.

56. The method of claim 55 , wherein the peptide linker comprises the amino acid sequence GGGGSGGGGS (SEQ ID NO: 48).

57. The method of claim 31 , wherein the second antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding domain via a peptide linker.

58. The method of claim 57 , wherein the peptide linker comprises the amino acid sequence GGGGSGGGGS (SEQ ID NO: 48).

59. The method of claim 34 , wherein the second antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding domain via a peptide linker.

60. The method of claim 59 , wherein the peptide linker comprises the amino acid sequence GGGGSGGGGS (SEQ ID NO: 48).

61. The method of claim 37 , wherein the second antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding domain via a peptide linker.

62. The method of claim 61 , wherein the peptide linker comprises the amino acid sequence GGGGSGGGGS (SEQ ID NO: 48).

63. The method of claim 40 , wherein the second antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding domain via a peptide linker.

64. The method of claim 63 , wherein the peptide linker comprises the amino acid sequence GGGGSGGGGS (SEQ ID NO: 48).

Priority Claims (1)
EP 20181056 · Jun 19, 2020 · regional
Continuity (2)
Division 17350111 · Jun 17, 2021
Related Publication 20240132590A1 · Apr 25, 2024
References Cited (268)
US 5571894A · Wels et al. · 1996 [cited by applicant]
US 5587458A · King · 1996 [cited by applicant]
US 5591828A · Bosslet et al. · 1997 [cited by applicant]
US 5731168A · Carter et al. · 1998 [cited by applicant]
US 5821337A · Carter et al. · 1998 [cited by applicant]
US 5869046A · Presta et al. · 1999 [cited by applicant]
US 6248516B1 · Winter et al. · 2001 [cited by applicant]
US 6737056B1 · Presta · 2004 [cited by applicant]
US 6809185B1 · Schoonjans et al. · 2004 [cited by applicant]
US 7332581B2 · Presta · 2008 [cited by applicant]
US 7695936B2 · Carter et al. · 2010 [cited by applicant]
US 8227577B2 · Klein et al. · 2012 [cited by applicant]
US 8242247B2 · Klein et al. · 2012 [cited by applicant]
US 8703132B2 · Imhof-Jung et al. · 2014 [cited by applicant]
US 8709421B2 · Heiss et al. · 2014 [cited by applicant]
US 8796424B2 · Croasdale et al. · 2014 [cited by applicant]
US 8969526B2 · Baehner et al. · 2015 [cited by applicant]
US 9068008B2 · Mossner et al. · 2015 [cited by applicant]
US 9266938B2 · Ast et al. · 2016 [cited by applicant]
US 9266967B2 · Klein et al. · 2016 [cited by applicant]
US 9382323B2 · Brinkmann et al. · 2016 [cited by applicant]
US 9447159B2 · Ast et al. · 2016 [cited by applicant]
US 9526797B2 · Gerdes et al. · 2016 [cited by applicant]
US 10392445B2 · Amann et al. · 2019 [cited by applicant]
US 10464981B2 · Amann et al. · 2019 [cited by applicant]
US 11267903B2 · Amann et al. · 2022 [cited by applicant]
US 11286300B2 · Ferrara Koller et al. · 2022 [cited by applicant]
US 20070111281A1 · Sondermann et al. · 2007 [cited by applicant]
US 20080241152A1 · Alitalo et al. · 2008 [cited by applicant]
US 20090252683A1 · Kischel et al. · 2009 [cited by applicant]
US 20100015133A1 · Igawa et al. · 2010 [cited by applicant]
US 20100150918A1 · Kufer et al. · 2010 [cited by applicant]
US 20100316645A1 · Imhof-Jung et al. · 2010 [cited by applicant]
US 20110293613A1 · Brinkmann et al. · 2011 [cited by applicant]
US 20120225071A1 · Klein et al. · 2012 [cited by applicant]
US 20120276125A1 · Ast et al. · 2012 [cited by applicant]
US 20130022601A1 · Brinkmann et al. · 2013 [cited by applicant]
US 20130058936A1 · Bruenker et al. · 2013 [cited by applicant]
US 20130058937A1 · Auer et al. · 2013 [cited by applicant]
US 20130060011A1 · Bruenker et al. · 2013 [cited by applicant]
US 20130078249A1 · Ast et al. · 2013 [cited by applicant]
US 20130171095A1 · Bernett et al. · 2013 [cited by applicant]
US 20140088295A1 · Smith et al. · 2014 [cited by applicant]
US 20140112914A1 · Nezu et al. · 2014 [cited by applicant]
US 20140154254A1 · Kannan et al. · 2014 [cited by applicant]
US 20140242079A1 · Bacac et al. · 2014 [cited by applicant]
US 20140242080A1 · Jaeger et al. · 2014 [cited by applicant]
US 20140288275A1 · Moore et al. · 2014 [cited by applicant]
US 20140294823A1 · Moore et al. · 2014 [cited by applicant]
US 20140294833A1 · Desjarlais et al. · 2014 [cited by applicant]
US 20140302064A1 · Moore · 2014 [cited by applicant]
US 20140322217A1 · Moore et al. · 2014 [cited by applicant]
US 20140363426A1 · Moore et al. · 2014 [cited by applicant]
US 20140370013A1 · Desjarlais et al. · 2014 [cited by applicant]
US 20140377270A1 · Moore et al. · 2014 [cited by applicant]
US 20150166661A1 · Chen et al. · 2015 [cited by applicant]
US 20150274845A1 · Bruenker et al. · 2015 [cited by applicant]
US 20150315296A1 · Schaefer et al. · 2015 [cited by applicant]
US 20150368351A1 · Vu et al. · 2015 [cited by applicant]
US 20150376287A1 · Vu et al. · 2015 [cited by applicant]
US 20160075785A1 · Ast et al. · 2016 [cited by applicant]
US 20160130347A1 · Bruenker et al. · 2016 [cited by applicant]
US 20160145354A1 · Bacac et al. · 2016 [cited by applicant]
US 20160175397A1 · Umana et al. · 2016 [cited by applicant]
US 20160200833A1 · Amann et al. · 2016 [cited by applicant]
US 20160208017A1 · Ast et al. · 2016 [cited by applicant]
US 20160208019A1 · Bacac et al. · 2016 [cited by applicant]
US 20160263240A1 · Ast et al. · 2016 [cited by applicant]
US 20160297881A1 · Vu et al. · 2016 [cited by applicant]
US 20160340399A1 · Amann et al. · 2016 [cited by applicant]
US 20160368985A1 · Hotzel et al. · 2016 [cited by applicant]
US 20170008971A1 · Dennis et al. · 2017 [cited by applicant]
US 20170096485A1 · Bacac et al. · 2017 [cited by applicant]
US 20170096495A1 · Bacac et al. · 2017 [cited by applicant]
US 20170114146A1 · Klein et al. · 2017 [cited by applicant]
US 20170174786A1 · Bacac et al. · 2017 [cited by applicant]
US 20170190783A1 · Bacac et al. · 2017 [cited by applicant]
US 20170209573A1 · Bacac et al. · 2017 [cited by applicant]
US 20170253670A1 · Klein et al. · 2017 [cited by applicant]
US 20170267783A1 · Nezu et al. · 2017 [cited by applicant]
US 20170306018A1 · Vu et al. · 2017 [cited by applicant]
US 20170306036A1 · Vu et al. · 2017 [cited by applicant]
US 20170306044A1 · Vu et al. · 2017 [cited by applicant]
US 20170327579A1 · Vu et al. · 2017 [cited by applicant]
US 20170327580A1 · Vu et al. · 2017 [cited by applicant]
US 20180230215A1 · Hofer et al. · 2018 [cited by applicant]
US 20180282409A1 · Ferrara Koller et al. · 2018 [cited by applicant]
US 20190194291A1 · Bruenker et al. · 2019 [cited by applicant]
US 20190382507A1 · Amann et al. · 2019 [cited by applicant]
US 20200190206A1 · Ferrara Koller et al. · 2020 [cited by applicant]
US 20200199234A1 · Georges et al. · 2020 [cited by applicant]
US 20200247904A1 · Amann et al. · 2020 [cited by applicant]
US 20200270347A1 · Freimoser-Grundschober et al. · 2020 [cited by applicant]
US 20200317774A1 · Hofer et al. · 2020 [cited by applicant]
US 20200325238A1 · Bacac et al. · 2020 [cited by applicant]
US 20200347115A1 · Duerr et al. · 2020 [cited by applicant]
US 20210009656A1 · Bruenker et al. · 2021 [cited by applicant]
US 20210070882A1 · Bacac et al. · 2021 [cited by applicant]
US 20210163617A1 · Ferrara Koller et al. · 2021 [cited by applicant]
US 20210253724A1 · Claus et al. · 2021 [cited by applicant]
US 20210403562A1 · Freimoser-Grundschober et al. · 2021 [cited by applicant]
US 20220213199A1 · Bujotzek et al. · 2022 [cited by applicant]
US 20220259318A1 · Bujotzek et al. · 2022 [cited by applicant]
US 20230159642A1 · Bujotzek et al. · 2023 [cited by applicant]
US 20230277662A1 · Freimoser-Grundschober et al. · 2023 [cited by applicant]
US 20230416365A1 · Georges et al. · 2023 [cited by applicant]
US 20230416411A1 · Bruenker et al. · 2023 [cited by applicant]
US 20240042022A1 · Freimoser-Grundschober et al. · 2024 [cited by applicant]
US 20240043535A1 · Amann et al. · 2024 [cited by applicant]
CA 2896370A1 · 2014 [cited by applicant]
CN 103748114A · 2014 [cited by applicant]
EP 0404097B1 · 1996 [cited by applicant]
EP 1870459A1 · 2007 [cited by applicant]
EP 1870459A4 · 2010 [cited by applicant]
EP 2578230A1 · 2013 [cited by applicant]
EP 2647707A1 · 2013 [cited by applicant]
EP 2647707A4 · 2014 [cited by applicant]
EP 1870459B1 · 2016 [cited by applicant]
JP 2008543339A · 2008 [cited by applicant]
JP 2012518404A · 2012 [cited by applicant]
JP 2018529733A · 2018 [cited by applicant]
RU 2651776C2 · 2018 [cited by applicant]
TW 201726719A · 2017 [cited by applicant]
WO WO9103493A1 · 1991 [cited by applicant]
WO WO199316185A2 · 1993 [cited by applicant]
WO WO9601126A1 · 1996 [cited by applicant]
WO WO9627011A1 · 1996 [cited by applicant]
WO WO9640210A1 · 1996 [cited by applicant]
WO WO9850431A2 · 1998 [cited by applicant]
WO WO9850431A3 · 1999 [cited by applicant]
WO WO0209573A2 · 2002 [cited by applicant]
WO WO2004106381A1 · 2004 [cited by applicant]
WO WO2005012493A2 · 2005 [cited by applicant]
WO WO2005044859A2 · 2005 [cited by applicant]
WO WO2006082515A2 · 2006 [cited by applicant]
WO WO2006121168A1 · 2006 [cited by applicant]
WO WO2007002223A2 · 2007 [cited by applicant]
WO WO2007024715A2 · 2007 [cited by applicant]
WO WO2007042261A2 · 2007 [cited by applicant]
WO WO2007075270A2 · 2007 [cited by applicant]
WO WO2007110205A2 · 2007 [cited by applicant]
WO WO2007146968A2 · 2007 [cited by applicant]
WO WO2007147901A1 · 2007 [cited by applicant]
WO WO2008031056A2 · 2008 [cited by applicant]
WO WO2007024715A3 · 2008 [cited by applicant]
WO WO2008119566A2 · 2008 [cited by applicant]
WO WO2008119567A2 · 2008 [cited by applicant]
WO WO2007024715A9 · 2009 [cited by applicant]
WO WO2009070642A1 · 2009 [cited by applicant]
WO WO2009080251A1 · 2009 [cited by applicant]
WO WO2009080252A1 · 2009 [cited by applicant]
WO WO2009080253A1 · 2009 [cited by applicant]
WO WO2009080254A1 · 2009 [cited by applicant]
WO WO2009089004A1 · 2009 [cited by applicant]
WO WO2010095031A2 · 2010 [cited by applicant]
WO WO2010115589A1 · 2010 [cited by applicant]
WO WO2010129304A2 · 2010 [cited by applicant]
WO WO2010136172A1 · 2010 [cited by applicant]
WO WO2010145792A1 · 2010 [cited by applicant]
WO WO2010145793A1 · 2010 [cited by applicant]
WO WO2010129304A3 · 2011 [cited by applicant]
WO WO2011028952A1 · 2011 [cited by applicant]
WO WO2011090754A1 · 2011 [cited by applicant]
WO WO2011090762A1 · 2011 [cited by applicant]
WO WO2011143545A1 · 2011 [cited by applicant]
WO WO2012058768A1 · 2012 [cited by applicant]
WO WO2012058768A8 · 2012 [cited by applicant]
WO WO2012073985A1 · 2012 [cited by applicant]
WO WO2012130831A1 · 2012 [cited by applicant]
WO WO2012158818A2 · 2012 [cited by applicant]
WO WO2012162067A2 · 2012 [cited by applicant]
WO WO2013019906A1 · 2013 [cited by applicant]
WO WO2013026831A1 · 2013 [cited by applicant]
WO WO2013026833A1 · 2013 [cited by applicant]
WO WO2013026837A1 · 2013 [cited by applicant]
WO WO2013096291A2 · 2013 [cited by applicant]
WO WO2013157953A1 · 2013 [cited by applicant]
WO WO2013157954A1 · 2013 [cited by applicant]
WO WO2014012085A2 · 2014 [cited by applicant]
WO WO2014022540A1 · 2014 [cited by applicant]
WO WO2014028560A2 · 2014 [cited by applicant]
WO WO2014047231A1 · 2014 [cited by applicant]
WO WO2014028560A3 · 2014 [cited by applicant]
WO WO2014081955A1 · 2014 [cited by applicant]
WO WO2014122251A2 · 2014 [cited by applicant]
WO WO2014131694A1 · 2014 [cited by applicant]
WO WO2014131711A1 · 2014 [cited by applicant]
WO WO2014131712A1 · 2014 [cited by applicant]
WO WO2014141152A2 · 2014 [cited by applicant]
WO WO2014151910A1 · 2014 [cited by applicant]
WO WO2014153002A1 · 2014 [cited by applicant]
WO WO2014122251A3 · 2014 [cited by applicant]
WO WO2014141152A3 · 2014 [cited by applicant]
WO WO2014191113A1 · 2014 [cited by applicant]
WO WO2015006749A2 · 2015 [cited by applicant]
WO WO2014191113A8 · 2015 [cited by applicant]
WO WO2015006749A3 · 2015 [cited by applicant]
WO WO2015048272A1 · 2015 [cited by applicant]
WO WO2015101588A1 · 2015 [cited by applicant]
WO WO2015150447A1 · 2015 [cited by applicant]
WO WO2016020065A1 · 2016 [cited by applicant]
WO WO2016036678A1 · 2016 [cited by applicant]
WO WO2016075278A1 · 2016 [cited by applicant]
WO WO2016079076A1 · 2016 [cited by applicant]
WO WO2016079081A1 · 2016 [cited by applicant]
WO WO2016156291A1 · 2016 [cited by applicant]
WO WO2016179003A1 · 2016 [cited by applicant]
WO WO2017055541A1 · 2017 [cited by applicant]
WO WO2017055314A1 · 2017 [cited by examiner]
WO WO2017194438A1 · 2017 [cited by applicant]
WO WO2018114748A1 · 2018 [cited by applicant]
WO WO2018127473A1 · 2018 [cited by applicant]
WO WO2019086499A1 · 2019 [cited by applicant]
WO WO2019175071A1 · 2019 [cited by applicant]
WO WO2020007817A1 · 2020 [cited by applicant]
WO WO2020127618A1 · 2020 [cited by applicant]
WO WO2020127619A1 · 2020 [cited by applicant]
WO WO2021046536A1 · 2021 [cited by applicant]
WO WO2021255138A1 · 2021 [cited by applicant]
WO WO2021255143A1 · 2021 [cited by applicant]
WO WO2021255146A1 · 2021 [cited by applicant]
U.S. Appl. No. 18/244,135, Hoffmann-La Roche Inc. [cited by applicant]
Almagro et al., “Humanization of antibodies,” Front Biosci. 13:1619-33 (2008). [cited by applicant]
Atwell et al., “Stable Heterodimers from Remodeling the Domain Interface of a Homodimer using a Phage Display Library,” J Mol Biol. 270(1):26-35 (1997). [cited by applicant]
Booy et al., “Monoclonal and bispecific antibodies as novel therapeutics,” Arch Immunol Ther Exp (Warsz). 54(2):85-101 (2006). [cited by applicant]
Bosch et al., “MCSP/CD3-bispecific single-chain antibody construct engages CD4+ and CD8+ T cells for lysis of MCSP-expressing human uveal melanoma cells,” AACR 101st Annual Meeting. April 17-21, Washington, DC. 70(8 Sup… [cited by applicant]
Carter, “Bispecific human IgG by design,” J Immunol Methods. 248(1-2):7-15 (2001). [cited by applicant]
Chan et al., “Variable region domain exchange in human IgGs promotes antibody complex formation with accompanying structural changes and altered effector functions,” Mol Immunol. 41(5):527-38 (2004). [cited by applicant]
Chelius et al., “Identification and Characterization of Deamidation Sites in the Conserved Regions of Human Immunoglobulin Gamma Antibodies,” Anal Chem. 77(18):6004-11 (2005). [cited by applicant]
Claus et al., “Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy,” available in PMC Apr. 24, 2020, published in final edited form as: Sci Transl Med. 11(496):eaav59… [cited by applicant]
Cui et al., “Chemically programmed bispecific antibodies that recruit and activate T cells,” J Biol Chem. 287(34):28206-14 (2012) (10 pages). [cited by applicant]
Edelman et al., “The covalent structure of an entire gammaG immunoglobulin molecule,” Proc Natl Acad Sci U S A. 63(1):78-85 (1969). [cited by applicant]
Hoffman et al., “Blinatumomab, a bi-specific anti-CD19/CD3 BITER antibody for the treatment of acute lymphoblastic leukemia: perspectives and current pediatric applications,” Front Oncol. 4(63):1-5 (2014). [cited by applicant]
Holliger et al., “Diabodies': small bivalent and bispecific antibody fragments,” Proc Natl Acad Sci U S A. 90(14):6444-8 (1993). [cited by applicant]
Holliger et al., “Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody,” Protein Eng. 9(3):299-305 (1996). [cited by applicant]
Honeychurch et al., “Bispecific Ab therapy of B-cell lymphoma: target cell specificity of antibody derivatives appears critical in determining therapeutic outcome,” Cancer Immunol Immunother. 45(3-4):171-3 (1997). [cited by applicant]
Hudson et al., “Engineered antibodies,” Nat Med. 9(1):129-34 (2003). [cited by applicant]
Husain et al., “Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies,” BioDrugs. 32(5):441-464 (2018). [cited by applicant]
Kipriyanov et al., “Bispecific CD3 x CD19 diabody for T cell-mediated lysis of malignant human B cells,” Int J Cancer. 77(5):763-72 (1998). [cited by applicant]
Kipriyanov et al., “Bispecific Tandem Diabody for Tumor Therapy with Improved Antigen Binding and Pharmacokinetics,” J Mol Biol. 293(1):41-56 (1999). [cited by applicant]
Klein et al., “Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies,” MAbs. 4(6):653-63 (2012). [cited by applicant]
Kontermann, “Dual targeting strategies with bispecific antibodies,” MAbs. 4(2):182-97 (2012). [cited by applicant]
Li et al., “Preparation of a Humanized Anti-CD3 Antibody Containing Mutated Constant Region and Its Biological Activity,” Chinese Journal of Biochemistry and Molecular Biology. 20(1):28-33 (2004). [cited by applicant]
Luiten et al., “Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (MOv18) and displays decreased immunogenicity in patients,” J Immunother. 20(6):496-504 (… [cited by applicant]
Merchant et al., “An efficient route to human bispecific IgG,” Nat Biotechnol. 16(7):677-81 (1998). [cited by applicant]
Miller et al., “Design, construction, and in vitro analyses of multivalent antibodies,” J Immunol. 170(9):4854-61 (2003). [cited by applicant]
Moore et al., “A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens,” MAbs. 3(6):546-57 (2011). [cited by applicant]
Moore et al., “Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma,” Blood. 117(17):4542-51 (2011) (11 pages). [cited by applicant]
Nagorsen et al., “Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab,” Exp Cell Res. 317(9):1255-60 (2011). [cited by applicant]
Oshimi et al., “Increased lysis of patient CD10-positive leukemic cells by T cells coated with anti-CD3 Fab' antibody cross-linked to anti-CD10 Fab' antibody,” Blood. 77(5):1044-9 (1991) (7 pages). [cited by applicant]
Pessano et al., “The T3/T cell receptor complex: antigenic distinction between the two 20-kd T3 (T3-delta and T3-epsilon) subunits,” EMBO J. 4(2):337-44 (1985). [cited by applicant]
Reusch et al., “A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells,” MAbs. 7(3):584-604 (2015) (22 pages). [cited by applicant]
Ridgway et al., “Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization,” Protein Eng. 9(7):617-21 (1996). [cited by applicant]
Riedle et al., “In vivo activation and expansion of T cells by a bi-specific antibody abolishes metastasis formation of human melanoma cells in SCID mice,” Int J Cancer. 75(6):908-18 (1998). [cited by applicant]
Sakuishi et al., “Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity,” J Exp Med. 207(10):2187-94 (2010). [cited by applicant]
Schaefer et al., “Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies,” Proc Natl Acad Sci U S A. 108(27):11187-92 (2011). [cited by applicant]
Seimetz et al., “Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy,” Cancer Treat Rev. 36(6):458-67 (2010). [cited by applicant]
Stubenrauch et al., “Impact of molecular processing in the hinge region of therapeutic IgG4 antibodies on disposition profiles in cynomolgus monkeys,” Drug Metab Dispos. 38(1):84-91 (2010). [cited by applicant]
Sun et al., “Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies,” Sci Transl Med. 7(287):287ra70 (2015) (11 pages). [cited by applicant]
Torisu-Itakura et al., “Redirected lysis of human melanoma cells by a MCSP/CD3-bispecific BiTE antibody that engages patient-derived T cells,” J Immunother. 34(8):597-605 (2011). [cited by applicant]
Tutt et al., “Trispecific F(ab′)3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells,” J Immunol. 147(1):60-9 (1991). [cited by applicant]
Weidle et al., “The intriguing options of multispecific antibody formats for treatment of cancer,” Cancer Genomics Proteomics. 10(1):1-18 (2013). [cited by applicant]
Wolf et al., “BiTEs: bispecific antibody constructs with unique anti-tumor activity,” Drug Discov Today. 10(18):1237-44 (2005). [cited by applicant]
Yokosuka et al., “Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2,” J Exp Med. 209(6):1201-17 (2012). [cited by applicant]
Zhu et al., “Identification of heavy chain residues in a humanized anti-CD3 antibody important for efficient antigen binding and T cell activation,” J Immunol. 155(4):1903-10 (1995). [cited by applicant]
English Translation of Search Report for Taiwanese Patent Application No. 110122112, dated Jun. 30, 2022 (2 pages). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/EP2021/066346, mailed Sep. 7, 2021 (20 pages). [cited by applicant]
Office Action with Search Report for Taiwanese Patent Application No. 110122112, dated Jul. 4, 2022 (8 pages) (partial translation included). [cited by applicant]
Cited By (2)
US 12,473,373 US 12,715,923